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The following recommendations apply to adult-type soft tissue
sarcomas arising from limbs and superficial trunk.
Recommendations on retroperitoneal sarcomas, desmoid-type
fibromatosis and uterine sarcomas are provided separately at
the end of the chapter with regard to those main aspects by
which they differ from more frequent soft tissue sarcomas. In
general, the main principles of diagnosis and treatment may
well apply to all soft tissue sarcomas, including the rarest
presentations [e.g. visceral sarcomas other than gastrointestinal
stromal tumors (GIST), head and neck sarcomas], which
therefore are not specifically covered. Specific histological types,
however, may deserve specific approaches, which may not be
covered hereafter, given the scope of these Recommendations.
Extraskeletal Ewing’s family tumors and embryonal and
alveolar rhabdomyosarcoma are covered by other ESMO
Clinical Recommendations, inasmuch as they need completely
different approaches. The same applies to GIST.
incidence
Adult soft tissue sarcomas are rare tumors, with an estimated
incidence averaging 4/100 000/year in Europe.
diagnosis
The standard approach to diagnosis consists of multiple core
needle biopsies. However, an excisional biopsy may be the most
practical option for <5 cm superficial lesions. An open biopsy
may be another option in selected cases. The biopsy should be
performed by a trained surgeon, or discussed between the
surgeon and the radiologist. It should be planned in such a way
that the biopsy pathway and the scar can be safely removed on
definitive surgery, and should be preceded by imaging
[contrast-enhanced magnetic resonance imaging (MRI) is the
preferred method for limb and superficial trunk lesions].
Histological diagnosis should be made according to the
World Health Organization (WHO) classification. The
malignancy grade should be provided in all cases in which this
is feasible based on available systems. In Europe, the Fe´de´ration
Nationale des Centres de Lutte Contre le Cancer (FNLCC)
grading system is generally used, which distinguishes three
malignancy grades. A core biopsy may underestimate the tumor
malignancy grade, so that, when preoperative treatment is an
option, radiological imaging may add to pathology in
providing the clinician with information that helps to estimate
the malignancy grade. Pathologic diagnosis relies on
morphology and immunohistochemistry. It should be
complemented by molecular pathology [fluorescent in situ
hybridisation (FISH), reverse transcription–polymerase chain
reaction (RT–PCR)], to be performed in a laboratory enrolled
in an external quality assurance program, in particular when
the clinical pathologic presentation is unusual or the histologic
diagnosis is doubtful. The tumor sample should be fixed in
formalin (Bouin fixation should be avoided, since it may impair
the feasibility of molecular analysis). Collection of fresh
frozen tissue and tumor imprints (touch preps) is encouraged
because new molecular pathology assessments may become
available at a later date and could be made in the patient’s
interest. Informed consent for tumor banking should be sought
that allows for later analysis and research, as long as this is
allowed by local and national guidelines.
Tumor site should be properly recorded. Tumor size and
tumor depth (in relation to the muscular fascia) should be
recorded, since they entail a prognostic value, along with the
tumor malignancy grade.
staging and risk assessment
The pathology report should include an appropriate
description of tumor margins (i.e. the status of inked margins
and the distance between tumor edge and the closest inked
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margins). This allows the assessment of marginal status (i.e.
whether the minimum margin is intralesional, marginal, wide
and distances from surrounding tissues). The pathologic
assessment of margins should be made in collaboration with
the surgeon.
The surgical report should provide details on the surgical
conduct with regard to possible contaminations (i.e. it should
mention whether the tumor was opened, etc.).
If preoperative treatment was carried out, the pathology
report should include a tumor response assessment. In contrast
to osteosarcoma and Ewing’s family of tumors, however, no
validated system is available at present in this regard, and no
percentage of residual ‘viable cells’ is considered to have
a specific prognostic significance. This depends on several
factors, including the presence of non-treatment-related
necrosis and hemorrhage and the heterogeneity of post-
treatment changes. A multidisciplinary judgement is
recommended, involving the pathologist and the radiologist.
A chest computed tomography (CT) scan is mandatory for
staging purposes. Depending on the histological type and other
clinical features, further staging assessments may be
recommended (e.g. regional lymph node assessment for
synovial sarcoma or epithelioid sarcoma, abdominal CT scan
for myxoid liposarcoma, etc.). The American Joint Committee
on Cancer (AJCC)/International Union against Cancer (UICC)
staging classification system stresses the importance of the
malignancy grade in sarcoma. However, its use in routine
practice is limited. In addition to grading, other prognostic
factors are tumor size and tumor depth. Of course, tumor
resectability is also important.
treatment
Soft tissue sarcomas are ubiquitous in their site of origin, and
are often treated with multimodality treatment.
Multidisciplinary treatment planning is therefore mandatory in
all cases (involving pathologists, radiologists, surgeons,
radiation therapists, medical oncologists and pediatric
oncologists if applicable). This should be carried out in
reference centres for sarcomas and/or within reference
networks sharing multidisciplinary expertise. These centres are
involved in ongoing clinical trials, in which sarcoma patients’
enrolment is highly encouraged. This centralized referral should
be pursued as from the time of the clinical diagnosis of
a suspect sarcoma. In practice, referral of all patients with
a lesion likely to be a sarcoma would be recommended.
Practically, this would mean referring all patients with a deep
mass of soft tissues, or with a superficial lesion of soft tissues
having a diameter of >5 cm.
limited disease
Surgery is the standard treatment for all patients with adult-
type, localized soft tissue sarcomas. It should be performed by
a surgeon specifically trained in the treatment of this disease.
The standard surgical procedure is a wide excision,
complemented by radiation therapy as standard treatment of
intermediate-high grade, deep tumors with a diameter of >5 cm
[II, A]. This implies removing the tumor with a rim of normal
tissue around. One centimeter has been selected as a cut-off in
some studies, but it is important to realize that the margin can
be minimal in the case of resistant anatomic barriers, such as
muscular fasciae, periostium and perineurium. A marginal
excision may be acceptable as an individualized option in
highly selected cases, in particular for extracompartmental
atypical lipomatous tumors.
While radiation therapy as an adjuvant to surgery is
a standard for intermediate-high grade, deep tumors with
a diameter of >5 cm, it is an option in selected cases of deep
lesions £5 cm or low-grade tumors. Compartmental resection
of an intracompartmental tumor, if performed, does not
require adjuvant radiation therapy. Radiation therapy should
be administered postoperatively, with the best technique
available, at a dose of 50–60 Gy, with fractions of 1.8–2 Gy,
possibly with boosts up to 66 Gy, depending on presentation
and quality of surgery. Alternatively, radiotherapy may be
carried out preoperatively, normally using a dose of 50 Gy.
Intraoperative radiation therapy (IORT) and brachytherapy are
options in selected cases.
Data have been provided that adjuvant chemotherapy might
improve, or at least delay, distant and local recurrence in high-
risk patients. A recent meta-analysis found a statistically
significant, limited benefit in terms of both survival and
relapse-free survival. However, studies are conflicting, and
a final demonstration of efficacy is lacking. It is also unknown
whether it may be especially beneficial in specific subgroups.
Therefore, adjuvant chemotherapy is not standard treatment in
adult-type soft tissue sarcomas, and can be proposed as an
option to the high-risk individual patient (having a G2–3, deep,
>5 cm tumor) for shared decision-making in conditions of
uncertainty [II, C]. The histological type may be considered in
the decision-making, since some types are felt to be more
chemosensitive, whereas others are less so. If the decision is
made to use chemotherapy as upfront treatment, it may well be
used preoperatively, at least in part. A local benefit may be
gained, facilitating surgery. In one large randomized phase III
study (in patients with G2–3, deep, >5 cm soft tissue
sarcomas), regional hyperthermia in addition to systemic
chemotherapy was associated with a local and disease-free
survival advantage.
Re-operation should be considered in case of R1 resections, if
adequate margins can be achieved without major morbidity,
taking into account tumor extent and tumor biology (e.g. it
may be spared in extracompartmental atypical lipomatous
tumors, etc.). In the case of R2 surgery, re-operation is
mandatory, possibly with preoperative treatments if adequate
margins cannot be achieved or surgery is mutilating. In the
latter case, the use of multimodal therapy with less radical
surgery requires a shared decision-making with the patient
under conditions of uncertainty. Plastic repairs and vascular
grafting should be used as needed, and the patient should be
properly referred if necessary. Radiation therapy will obviously
follow marginal or R1–R2 excisions, if these cannot be rescued
through re-excision, even outside the usual indications. In non-
resectable tumors, or those amenable only to mutilating surgery
(in this case, on an individualized basis after sharing the
decision with the patient in conditions of uncertainty),
chemotherapy and/or radiotherapy, or isolated hyperthermic
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limb perfusion with tumor necrosis factor-alpha (TNFa) +
melphalan, if the tumor is confined to an extremity, or
regional hyperthermia combined with chemotherapy are
options.
Regional lymph node metastases should be distinguished
from soft tissue metastases involving lymph nodes. They are
rare, and constitute an adverse prognostic factor in adult-type
soft tissue sarcomas. More aggressive treatment planning is
therefore felt to be appropriate for these patients, although
there is a lack of formal evidence to indicate that this improves
clinical results. Surgery through wide excision (mutilating
surgery is exceptionally done given the prognosis of these
patients) may be coupled with adjuvant radiation therapy and
adjuvant chemotherapy for sensitive histological types, as
standard treatment for these presentations. Chemotherapy may
be administered as preoperative treatment, at least in part.
These treatment modalities adding to surgery should not be
viewed as truly ‘adjuvant’, the context being in fact that of
a likely systemic disease. In one large randomized phase III
study (in patients with G2–3, deep, >5 cm soft tissue sarcomas),
regional hyperthermia in addition to systemic chemotherapy
was associated with a local and disease-free survival
advantage. Isolated limb perfusion may be an option in this
patient population, along with chemotherapy and radiation
therapy.
The standard approach to local relapse parallels the approach
to primary local disease, except for a wider resort to
preoperative or postoperative radiation therapy, if not
previously performed.
extensive disease
In the case of synchronous lung metastases without
extrapulmonary disease, standard treatment is chemotherapy
[IV, B]. Especially when a tumor response is achieved, surgery
of completely resectable lung metastases may be offered as an
option. Metachronous resectable, and reasonably limited, lung
metastases without extrapulmonary disease are managed with
complete excision of all visible lesions as standard treatment
[IV, B]. Chemotherapy may be added as an option, taking into
account the prognostic factors (a short previous free interval
and a high number of lesions are adverse factors, encouraging
the addition of chemotherapy), although there is a lack of
formal evidence that this improves results. Chemotherapy is
preferably given before surgery, in order to assess tumor
response and thus modulate the length of treatment.
Extrapulmonary disease is treated with chemotherapy as
standard treatment [I, A]. In highly selected cases surgery of
responding metastases, whether pulmonary or possibly
extrapulmonary, may be offered as an option following a
multidisciplinary evaluation, taking into consideration their
site and the natural history of the disease in the individual
patient. Best supportive care may be another option in selected
cases.
Standard chemotherapy is based on anthracyclines as first
line treatment [I, A]. There is no formal demonstration that
multiagent chemotherapy is superior to single-agent
chemotherapy with doxorubicin alone. However, a higher
response rate may be expected, in particular in a number of
sensitive histological types, according to several, although not
all, randomized clinical trials.
Therefore, multiagent chemotherapy with doxorubicin plus
ifosfamide may be the treatment of choice, especially when
a tumor response is felt to be able to give an advantage and the
performance status is good. Dacarbazine may be added to the
regimen. In angiosarcoma, taxanes are an alternative option,
given their high antitumor activity in this specific histological
type [IV, B]. Taxanes are obviously an option also for
second-line chemotherapy in this subtype. Imatinib is standard
medical therapy for those rare patients with
dermatofibrosarcoma protuberans who are not amenable to
surgery or with metastases deserving medical therapy [IV, B].
Patients who have already received chemotherapy may be
treated with ifosfamide, if they did not receive it previously.
High-dose ifosfamide may be an option also for patients who
have already received standard-dose ifosfamide [IV, C].
Trabectedin is a second-line option [II, B]. It has proved
effective in leiomyosarcoma and liposarcoma. In myxoid
liposarcoma a peculiar pattern of tumor response has been
reported, with an early phase of tissue changes preceding tumor
shrinkage. Responses have been obtained in other histological
types, including synovial sarcoma. Randomized evidence was
provided that gemcitabine + docetaxel is more effective than
gemcitabine alone as second-line chemotherapy [II, D].
Gemcitabine was shown to have antitumor activity in
leiomyosarcoma also as a single agent. Dacarbazine has some
activity as second-line therapy (possibly mostly in
leiomyosarcoma). Best supportive care is an option for pretreated
patients with advanced soft tissue sarcoma, all the more if further-
line therapies have already been used in the patient.
follow-up
There are no published data supporting specific policies for
follow-up of surgically treated patients with localized disease.
Relapses most often occur to the lungs. The malignancy grade
likely affects the speed at which relapses may take place. The
risk assessment based on tumor grade, tumor size and tumor
site may help in choosing the routine follow-up policy. High-
risk patients generally relapse within 2–3 years, while low-risk
patients may relapse later, although it is less likely. Early
detection of local or metastatic recurrence to the lungs may
have prognostic implications, and lung metastases are
asymptomatic at a stage in which they are suitable for surgery.
Therefore, routine follow-up may focus on these sites. The best
method of follow-up has not been established. Although the use
of MRI to detect local relapse and CT to scan for lung
metastases is likely to pick up recurrence earlier, it is yet to be
demonstrated that this is beneficial or cost effective
compared with clinical assessment of the primary site and
regular chest X-rays.
The surgically treated intermediate/high grade patient may
be followed every 3–4 months in the first 2–3 years, then twice
a year up to the fifth year and once a year thereafter. Low-grade
sarcoma patients may be followed for local relapse every 4–6
months, with chest X-rays or CT scan at more relaxed intervals
in the first 3–5 years, then yearly.
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special presentations and entities
retroperitoneal sarcomas
Core needle biopsies are the standard procedure for diagnosis
in retroperitoneal sarcomas. An open biopsy may be an option
in selected cases. In both cases, the pathway of the biopsy
should be carefully planned to avoid contamination and
complications. However, radiological imaging may be sufficient
for the diagnosis of lipomatous tumors, if no preoperative
treatment is planned. Standard treatment for localized lesions is
surgery, which is best performed through a retroperitoneal
compartmental resection (i.e. complete excision of the tumor,
along with en-bloc visceral resections) [IV, D]. Preoperative
treatment may be an option, including radiation therapy,
chemotherapy, chemoradiation therapy, regional hyperthermia
in addition to chemotherapy. Adjuvant chemotherapy is an
option as for high-risk localized soft tissue sarcoma of limbs
and superficial trunk.
uterine sarcomas
This group includes leiomyosarcomas, endometrial stromal
sarcomas, undifferentiated endometrial sarcomas and pure
heterologous sarcomas. Carcinosarcomas (malignant Mullerian
mixed tumors) are mixed epithelial and mesenchymal
neoplasms, whose treatment may well follow their mainly
epithelial nature.
Standard treatment for all these tumors, when localized, is
total abdominal hysterectomy, although for endometrial
stromal sarcomas bilateral salpingooophorectomy is generally
performed, due to the hormonal sensitivity of these tumors,
and lymphadenectomy may be an option, given the possible
higher incidence of nodal involvement [IV, D]. As far as
leiomyosarcomas and high-grade undifferentiated sarcomas are
concerned, bilateral salpingooophorectomy, particularly in
premenopausal women, as well as lymphadenectomy, is not
demonstrated to be useful in the lack of macroscopic
involvement. Radiation therapy has not improved survival and
relapse-free survival in a randomized setting, although
retrospective studies suggested a possible decrease in local
relapses. Therefore, its use as an adjuvant to surgery may only
be an option in selected cases, after shared decision-making
with the patient [III, C]. The systemic treatment of metastatic
endometrial stromal sarcomas exploits their sensitivity to
hormonal therapies [V, D]. Therefore, progestins are generally
used, along with Gn-RH analogues and aromatase inhibitors.
Tamoxifen is contraindicated, as well as hormonal replacement
therapy containing estrogens. Surgery of lung metastases is an
option, given the natural history of the disease. The systemic
treatment of leiomyosarcomas, undifferentiated endometrial
sarcomas and pure heterologous sarcomas parallels that for
adult-type soft tissue sarcomas.
desmoid-type aggressive fibromatosis
Standard treatment for primary disease, if amenable to surgery
without significant functional losses, is wide excision [IV, B]. In
those cases in which only marginal excision can be performed,
postoperative radiation therapy is an option, after sharing the
decision with the patient in conditions of uncertainty,
considering the possible occurrence of radiation-related high
grade sarcomas in a non-metastasizing disease. Observation is
another option in selected cases, after shared decision-making
with the patient, taking into account the indolent natural
history of some clinical presentations. For primary disease only
amenable to surgery with significant functional losses, wide
excision is an option, along with radiation therapy, observation,
isolated limb perfusion (if the lesion is confined to an
extremity) or systemic therapy (see below) [V, D]. The same
applies to recurrent disease. For the inoperable disease,
radiation therapy, ILP (if the lesion is confined to an
extremity), and systemic therapies are options, along with
observation [V, D]. Systemic therapies include: hormonal
therapies (tamoxifen, toremifene, Gn-RH analogues), non-
steroidal anti-inflammatory drugs; low-dose chemotherapy,
such as methotrexate + vinblastine or methotrexate +
vinorelbine; low-dose interferon; imatinib; full-dose
chemotherapy (using regimens active in sarcomas). It is
reasonable to employ the less toxic therapies before the more
toxic in a stepwise fashion.
notes
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts and
the ESMO Faculty.
These Clinical Recommendations update those formulated in
2008 following a consensus process based on a consensus event
organized by ESMO in Lugano in October 2007. The consensus
update in early 2009 and the previous event involved the same
experts from the community of the European sarcoma research
groups and from some sarcoma reference centres outside
Europe. Their names are indicated hereafter. The text reflects
an overall consensus among them, although each of them may
not necessarily find it consistent with his/her own views. The
EU-funded network of excellence CONTICANET (CONnective
TIssue CAncers NETwork) supported the consensus process.
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